Document is current
Any future updates will be listed below
-
Authors
Ryu, Jae Kyu https://orcid.org/0000-0002-3992-4011
Yan, Zhaoqi https://orcid.org/0000-0001-9326-2920
Montano, Mauricio https://orcid.org/0000-0002-0353-0037
Sozmen, Elif G.
Dixit, Karuna https://orcid.org/0000-0003-3583-2512
Suryawanshi, Rahul K. https://orcid.org/0000-0001-8374-669X
Matsui, Yusuke https://orcid.org/0000-0002-6016-2867
Helmy, Ekram
Kaushal, Prashant
Makanani, Sara K.
Deerinck, Thomas J.
Meyer-Franke, Anke
Rios Coronado, Pamela E.
Trevino, Troy N.
Shin, Min-Gyoung
Tognatta, Reshmi https://orcid.org/0000-0001-7460-1843
Liu, Yixin https://orcid.org/0000-0003-1135-2805
Schuck, Renaud
Le, Lucas https://orcid.org/0009-0005-7794-5736
Miyajima, Hisao
Mendiola, Andrew S. https://orcid.org/0000-0002-2897-3299
Arun, Nikhita
Guo, Brandon
Taha, Taha Y. https://orcid.org/0000-0002-7344-7490
Agrawal, Ayushi https://orcid.org/0000-0003-2940-8926
MacDonald, Eilidh
Aries, Oliver
Yan, Aaron
Weaver, Olivia
Petersen, Mark A. https://orcid.org/0000-0003-1366-1353
Meza Acevedo, Rosa
Alzamora, Maria del Pilar S. https://orcid.org/0000-0001-8861-387X
Thomas, Reuben
Traglia, Michela
Kouznetsova, Valentina L.
Tsigelny, Igor F.
Pico, Alexander R. https://orcid.org/0000-0001-5706-2163
Red-Horse, Kristy https://orcid.org/0000-0003-1541-601X
Ellisman, Mark H. https://orcid.org/0000-0001-8893-8455
Krogan, Nevan J.
Bouhaddou, Mehdi
Ott, Melanie https://orcid.org/0000-0002-5697-1274
Greene, Warner C. https://orcid.org/0000-0001-9896-8615
Akassoglou, Katerina https://orcid.org/0000-0002-2632-1465
- License Information
-
More Information
Article History
Received: 13 February 2023
Accepted: 24 July 2024
First Online: 28 August 2024
Competing interests
: K.A. is listed as an inventor on US patents 7,807,645, 8,569,242, 8,877,195 and 8,980,836, covering fibrin antibodies, submitted by the University of California. K.A. and J.K.R. are listed as co-inventors on US patent 9,669,112 covering fibrin in vivo models, and US patents 10,451,611 and 11,573,222 covering in vitro fibrin assays submitted by Gladstone Institutes. K.A., J.K.R., M.M. and W.C.G. are listed as co-inventors on US patent 12,016,934 covering the COVID-induced thromboinflammation model and US patent application 18/267,710 for use of fibrin immunotherapy in COVID-19 submitted by Gladstone Institutes. K.A. is a co-founder and scientific advisor of Therini Bio. K.A. has served as a consultant for F. Hoffman-La Roche not related to this study. W.C.G. is a co-founder and shareholder in InvisiShield Technologies, but work in this company has no overlap with the topic or findings presented in this paper. M.O. is a founder of DirectBio and is on the scientific advisory board of InvisiShield, but both are scientifically unrelated to this study. The Krogan Laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche and Rezo Therapeutics unrelated to this study. N.J.K. has a financially compensated consulting agreement with Maze Therapeutics, is the president and is on the board of directors of Rezo Therapeutics, and is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics, GEn1E Lifesciences and Interline Therapeutics, but all are unrelated to this study. Their interests are managed in accordance with their respective institutions’ conflict of interest policies. The other authors declare no competing interests.
